Company research
Ventyx Biosciences, Inc.
CIK 1851194Updated Oct 6, 2026
Historical securities (1)
VTYX · NASDAQ · equity · closed Mar 4, 2026VTYX price & chart
This listing closed Mar 4, 2026. Live provider charts are shown only for current listings.
About the company
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with inflammation-mediated diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials. Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that demonstrated significant reductions in cardiovascular risk factors in a recently reported Phase 2 trial. In addition, VTX3232 recently completed a Phase 2 biomarker study in early-stage Parkinson’s disease. Our broader inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), a S1P1R modulator and VTX958, a TYK2 inhibitor.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 211,465,000Source | 301,100,000Source | 321,701,000Source | 230,009,000Source | 309,193,000Source | 348,763,000Source | 253,480,000Source | 332,078,000Source | 276,563,000Source | 277,693,000Source | 371,400,000Source | 291,482,000Source |
| Property, Plant and Equipment, NetUSD | 501,000Source | 703,000Source | 686,000Source | 549,000Source | 762,000Source | 629,000Source | 522,000Source | 828,000Source | 614,000Source | 762,000Source | 407,000Source | 254,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 31,970,000Source | 61,765,000Source | 56,610,000Source | 32,301,000Source | 40,925,000Source | 51,717,000Source | 28,076,000Source | 141,898,000Source | 27,260,000Source | 51,579,000Source | 64,819,000Source | 70,791,000Source |
| Assets, CurrentUSD | 201,094,000Source | 289,408,000Source | 308,092,000Source | 219,322,000Source | 256,931,000Source | 346,701,000Source | 242,558,000Source | 319,759,000Source | 229,625,000Source | 264,345,000Source | 330,688,000Source | 263,020,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,883,000Source | 9,918,000Source | 11,846,000Source | 9,151,000Source | 10,162,000Source | 1,331,000Source | 9,413,000Source | 10,414,000Source | 9,669,000Source | 11,509,000Source | 1,537,000Source | — |
| Other Assets, NoncurrentUSD | 12,000Source | 96,000Source | 102,000Source | 12,000Source | 102,000Source | 102,000Source | 12,000Source | 102,000Source | 59,000Source | 102,000Source | 96,000Source | 60,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 20,101,000Source | 22,328,000Source | 38,061,000Source | 20,626,000Source | 28,398,000Source | 20,956,000Source | 21,847,000Source | 25,082,000Source | 22,518,000Source | 33,770,000Source | 17,505,000Source | 12,283,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 6,000Source | 7,000Source | 7,000Source | 6,000Source | 7,000Source | 7,000Source | 7,000Source | 6,000Source | 6,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 822,699,000Source | 802,850,000Source | 656,575,000Source | 817,864,000Source | 770,745,000Source | 646,918,000Source | 813,221,000Source | 764,869,000Source | 808,190,000Source | 663,154,000Source | 581,237,000Source | 397,051,000Source |
| Retained Earnings (Accumulated Deficit)USD | -631,565,000Source | -524,958,000Source | -372,434,000Source | -608,736,000Source | -489,709,000Source | -318,407,000Source | -581,749,000Source | -457,759,000Source | -554,309,000Source | -419,187,000Source | -226,225,000Source | -117,799,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 223,000Source | 873,000Source | -507,000Source | 248,000Source | -248,000Source | -710,000Source | 154,000Source | -121,000Source | 157,000Source | -50,000Source | -1,123,000Source | -58,000Source |
| Stockholders' Equity Attributable to ParentUSD | 191,364,000Source | 278,772,000Source | 283,640,000Source | 209,383,000Source | 280,795,000Source | 327,807,000Source | 231,633,000Source | 306,996,000Source | 254,045,000Source | 243,923,000Source | 353,895,000Source | 279,199,000Source |
| Liabilities and EquityUSD | 211,465,000Source | 301,100,000Source | 321,701,000Source | 230,009,000Source | 309,193,000Source | 348,763,000Source | 253,480,000Source | 332,078,000Source | 276,563,000Source | 277,693,000Source | 371,400,000Source | 291,482,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,259,000Source | 12,303,000Source | 26,208,000Source | 11,469,000Source | 18,104,000Source | 20,034,000Source | 12,394,000Source | 14,534,000Source | 12,776,000Source | 22,265,000Source | 16,359,000Source | 12,283,000Source |
| Operating Lease, Liability, CurrentUSD | 1,182,000Source | 1,011,000Source | 479,000Source | 1,138,000Source | 971,000Source | 439,000Source | 1,094,000Source | 946,000Source | 1,052,000Source | 1,001,000Source | 412,000Source | — |
| Accounts Payable, CurrentUSD | 993,000Source | 2,286,000Source | 9,338,000Source | 913,000Source | 6,583,000Source | 4,085,000Source | 2,320,000Source | 5,583,000Source | 3,130,000Source | 5,756,000Source | 6,433,000Source | 4,661,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,842,000Source | 10,025,000Source | 11,853,000Source | 9,157,000Source | 10,294,000Source | 922,000Source | 9,453,000Source | 10,548,000Source | 9,742,000Source | 11,505,000Source | 1,146,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,084,000Source | 9,006,000Source | 16,391,000Source | 9,418,000Source | 10,550,000Source | 15,510,000Source | 8,980,000Source | 8,005,000Source | 8,594,000Source | 15,508,000Source | 9,514,000Source | 7,622,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 252,900,000Source | 252,200,000Source | 356,600,000Source | 286,700,000Source |
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -27,440,000Source | -38,572,000Source | -135,122,000Source | -192,962,000Source | -108,426,000Source | -83,746,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,031,000Source | 6,543,000Source | 22,931,000Source | 28,588,000Source | 16,570,000Source | 2,730,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -809,000Source | -1,190,000Source | -2,644,000Source | -745,000Source | 1,613,000Source | 2,443,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -25,718,000Source | -47,625,000Source | -130,873,000Source | -166,522,000Source | -98,771,000Source | -38,650,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | -1,899,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 26,415,000Source | 41,765,000Source | -15,506,000Source | 100,940,000Source | -74,931,000Source | -214,365,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 16,000Source | 175,000Source | 241,000Source | 514,000Source | 275,000Source | 262,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 96,184,000Source | 122,115,000Source | 53,329,000Source | 167,772,000Source | 323,551,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 816,000Source | 90,319,000Source | -24,319,000Source | -12,265,000Source | -5,972,000Source | 70,547,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 32,945,000Source | 62,740,000Source | 33,276,000Source | 41,900,000Source | 29,051,000Source | 142,873,000Source | 28,235,000Source | 52,554,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,601,000Source | 5,451,000Source | 4,575,000Source | 5,771,000Source | 5,031,000Source | 6,543,000Source | 22,931,000Source | 28,588,000Source | 16,570,000Source | 2,730,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 252,900,000Source | 252,200,000Source | 356,600,000Source | 286,700,000Source |
| DepreciationUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 70,000Source | 266,000Source | 158,000Source | 123,000Source | 30,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | -98,000Source | -136,000Source | — | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | 88,000Source | 88,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 7,168,000Source | 7,923,000Source | 7,067,000Source | 7,907,000Source | 7,199,000Source | 8,021,000Source | 31,448,000Source | 32,227,000Source | 25,398,000Source | 8,666,000Source |
| Investment Income, InterestUSD | — | — | 2,055,000Source | 3,350,000Source | 2,367,000Source | 3,783,000Source | 2,666,000Source | 3,227,000Source | 13,416,000Source | 15,074,000Source | 4,669,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,829,000Source | -35,249,000Source | -26,987,000Source | -31,950,000Source | -27,440,000Source | -38,572,000Source | -135,122,000Source | -192,962,000Source | -108,426,000Source | -83,746,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -108,426,000Source | -85,298,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,045,000Source | 3,303,000Source | 2,346,000Source | 3,762,000Source | 2,657,000Source | 3,196,000Source | 13,328,000Source | 15,032,000Source | 4,710,000Source | -16,599,000Source |
| Operating ExpensesUSD | — | — | 24,874,000Source | 38,552,000Source | 29,333,000Source | 35,712,000Source | 30,097,000Source | 41,768,000Source | 148,450,000Source | 207,994,000Source | 113,136,000Source | 67,147,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,000Source | -47,000Source | -21,000Source | -21,000Source | -9,000Source | -31,000Source | -88,000Source | -42,000Source | 41,000Source | 27,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 92,000Source | 261,000Source | 4,671,000Source | 2,107,000Source | 65,000Source |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -24,874,000Source | -38,552,000Source | -29,333,000Source | -35,712,000Source | -30,097,000Source | -41,768,000Source | -148,450,000Source | -207,994,000Source | -113,136,000Source | -67,147,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,000Source | -47,000Source | -21,000Source | -21,000Source | -9,000Source | -31,000Source | -88,000Source | -42,000Source | 41,000Source | 27,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -135,086,000Source | -192,931,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -22,829,000Source | -35,249,000Source | -26,987,000Source | -31,950,000Source | -27,440,000Source | -38,572,000Source | -135,122,000Source | -192,962,000Source | -108,426,000Source | -83,746,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.32Source | -0.5Source | -0.38Source | -0.45Source | -0.39Source | -0.62Source | -1.97Source | -3.3Source | -2.07Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.32Source | -0.5Source | -0.38Source | -0.45Source | -0.39Source | -0.62Source | -1.97Source | -3.3Source | -2.07Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 71,304,084Source | 70,667,570Source | 71,198,652Source | 70,554,718Source | 71,131,439Source | 61,829,976Source | 68,478,172Source | 58,542,974Source | 52,471,003Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 71,304,084Source | 70,667,570Source | 71,198,652Source | 70,554,718Source | 71,131,439Source | 61,829,976Source | 68,478,172Source | 58,542,974Source | 52,471,003Source | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 7,168,000Source | 7,923,000Source | 7,067,000Source | 7,907,000Source | 7,199,000Source | 8,021,000Source | 31,448,000Source | 32,227,000Source | 25,398,000Source | 8,666,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -40,775,000Source | -121,383,000Source | -52,073,000Source | — |
| Investment Income, InterestUSD | — | — | 2,055,000Source | 3,350,000Source | 2,367,000Source | 3,783,000Source | 2,666,000Source | 3,227,000Source | 13,416,000Source | 15,074,000Source | 4,669,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -108,426,000Source | -85,298,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,045,000Source | 3,303,000Source | 2,346,000Source | 3,762,000Source | 2,657,000Source | 3,196,000Source | 13,328,000Source | 15,032,000Source | 4,710,000Source | -16,599,000Source |
| Operating ExpensesUSD | — | — | 24,874,000Source | 38,552,000Source | 29,333,000Source | 35,712,000Source | 30,097,000Source | 41,768,000Source | 148,450,000Source | 207,994,000Source | 113,136,000Source | 67,147,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | — | 1,552,000Source |
| Research and Development ExpenseUSD | — | — | 17,706,000Source | 30,629,000Source | 22,266,000Source | 27,805,000Source | 22,898,000Source | 33,747,000Source | 117,002,000Source | 175,767,000Source | 87,738,000Source | 58,481,000Source |
Offerings
Registration 333-278584
Registration 333-283076
Filing attachments
ex99_1.htm · SCHEDULE 13G/A · 2026-05-15
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of Ventyx Biosciences, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agr…
Read attachment ↗d98679dex991.htm · 8-K · 2026-01-07
Exhibit 99.1 Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Ventyx’s clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly’s established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ - Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmac…
Read attachment ↗vtyx-ex99_1.htm · 8-K · 2025-11-06
EX-99.1 2 vtyx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress • Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease • Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s disease • Topline d…
Read attachment ↗d98315dex991.htm · 8-K · 2025-10-22
EX-99.1 2 d98315dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first week VTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for c…
Read attachment ↗d98315dex992.htm · 8-K · 2025-10-22
EX-99.2 3 d98315dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results October 22, 2025 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking …
Read attachment ↗vtyx-ex99_1.htm · 8-K · 2025-08-07
EX-99.1 2 vtyx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress • Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease • Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 • Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors i…
Read attachment ↗